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Hearing impairment (HI) is a significant disability, affecting ~278 
million people globally.[1] The burden inflicted by HI, like those of 
diabetes mellitus (DM) and hypertension (HPT), is felt to the greatest 
extent in low- to middle-income countries.[1]
DM is a metabolic disorder capable of causing both micro- and 
macrovascular complications. The cochlea and auditory nerves 
are therefore at risk from these DM-related complications, in the 
form of microangiopathy, neuropathy or mitochondrial damage.[2,3] 
Although HI has been observed for decades in people living with 
diabetes (PLWD), there is still considerable debate as to whether HI 
and DM are related. Globally, studies have shown that the prevalence 
of HI in PLWD ranges from 13% to 95%.[4-7] This relationship has 
been documented in patients with both types 1 and 2 DM.[5,6,8,9] In 
contrast, studies by Harner,[10] Schuknecht[11] and Bainbridge et al.,[12] 
among others, have shown that there is no association between DM 
and HI.
When present, HI in PLWD is usually bilateral,[13-16] and symptoms 
can range from tinnitus to dizziness, subjective HI and vertigo, 
while some patients are asymptomatic.[17-19] Poor glycaemic control 
is associated with increased risks of DM-related complications.[20] 
HI as a complication would appear to be no different. However, the 
relationship between glycaemic control in PLWD and HI remains 
controversial. Lerman-Garber et al.[14] and Agrawal et al.[15] found 
positive correlations between poorly controlled DM and HI. In 
contrast, Ashkezari et al.,[21] Bainbridge et al.[12] and Kakarlapudi et al.[4] 
found no such association.
Results of studies performed globally have been conflicting with 
regard to HI and duration of DM,[7,13,17,21] gender,[5,13,22,23] patient 
age[13,24,25] and type of antidiabetic therapy.[4,12,26-28] Similarly, findings 
with regard to the relationship between DM-related complications 
and HI have also been inconclusive, with some studies demonstrating 
a positive relationship between DM-related neuropathy[12,22] and 
retinopathy[21] and HI, while others showed none.[14] Bainbridge et 
al.[12] showed that patients with HI had an increased prevalence of 
albuminuria, while Shen and Hsieh[29] demonstrated that HI was 
linked to serum creatinine levels and inversely related to glomerular 
filtration rate (GFR).
Obesity remains a major hurdle in the optimal management 
of DM. Both Curhan et al.[30] and Fransen et al.[31] demonstrated 
a positive correlation between body mass index (BMI) and HI. 
Hyperlipidaemia is a common comorbidity in PLWD and is a risk 
factor for cardiovascular morbidity and mortality. Swaminathan 
et al.[32] showed that increased total cholesterol (TC), increased 
triglycerides and increased low-density lipoprotein cholesterol (LDL-
C) can each increase the risk of HI in PLWD. Evans et al.[33] and 
Dabrowski et al.[24] demonstrated the same association between 
triglyceride level and HI. High-density lipoprotein cholesterol (HDL-
C) is known to have cardioprotective properties.[34] Suzuki et al.,[35] 
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Background. Diabetes mellitus (DM) causes both micro- and macrovascular complications. The cochlea and auditory nerves are therefore 
at increased risk from DM-related complications due to microangiopathy, neuropathy or mitochondrial damage. Limited data are available 
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Objectives. To describe the prevalence and spectrum of and associations with HI in patients living with DM (PLWD) with and without 
HIV infection.
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Results. A total of 296 PLWD (89.2% with type 2 DM) were enrolled, of whom 154 (52.0%) had HI. Type 2 PLWD had a significantly 
higher prevalence of reported symptoms and confirmed audiological HI, which was most often bilateral. The most frequent HI categories 
were mild to moderate, mild, and moderate to severe (33.8% v. 25.9% v. 23.9%, respectively). Significant associations were noted between 
dizziness (p=0.045), reported hearing loss (p<0.001) and objective evidence of HI (all categories except mild). HI was significantly associated 
with age >50 years, DM duration ≤10 years, female gender, hypertension, increased low-density lipoprotein and total cholesterol (TC), lower 
high-density lipoprotein cholesterol, suboptimal glycaemic control, non-proliferative retinopathy, sensory neuropathy and obesity (p<0.05). 
Approximately half (48.9%) of PLWD and HIV infection had HI, and they were significantly younger and had higher TC levels than PLWD 
without HIV (p<0.05).
Conclusions. We showed that HI occurs in over half of PLWD, usually within the first 10 years after diagnosis of DM. Symptoms of HI 
were shown to have positive associations with all HI categories except mild. A high level of vigilance for HI must be maintained in PLWD.
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Bainbridge et al.[12] and Dabrowski et al.[24] have found that low levels 
of HDL-C are associated with an increased risk of HI.
Limited data relating to DM and HI are available from Africa and 
South Africa (SA). In their study conducted in Nigeria, a country 
similar to SA in terms of its economy, Idugboe et al.[28] showed that 
HI was common in PLWD (71.4%) and that the HI was not associated 
with gender, duration of DM or glycaemic control. They showed 
that HI occurred earlier in Nigerian patients compared with other 
studies such as the Wisconsin[36] and Blue Mountains[37] studies, 
conducted in the USA and Australia, respectively. Most of the PLWD 
in Idugboe et al.’s[28] study had mild HI, followed by moderate and 
severe categories (44.3%, 21.4% and 5.7%, respectively), and were 
<50 years of age; however, it must be noted that their study only 
included patients between 31 and 64 years of age, and excluded 
patients with HPT and/or chronic kidney disease.
The only other African study describing HI in PLWD was done 
in SA by Hlayisi et al.,[38] who found that HI was increased in PLWD 
(55%), was common in patients <49 years of age, was more prevalent 
in males than in females, and had a positive correlation with duration 
of DM. However, they found no link between glycated haemoglobin 
(HbA1c) and HI.
Objectives
Having accepted that the majority of studies have demonstrated 
that there is an association between DM and HI, our objectives 
were first to describe the spectrum of HI in PLWD and then to 
determine whether any of the associations mentioned above between 
HI and PLWD were validated in patients visiting a diabetes clinic at 
a regional hospital in Pietermaritzburg, KwaZulu-Natal Province. 
Interestingly, none of the studies mentioned earlier, which were done 
in both developed and developing countries, assessed whether there 
was any association between HI and HIV infection in PLWD. This 
correlation was also searched for in our study.
Methods
This was an analytical cross-sectional study conducted between 
1 October and 31 December 2019 at the Edendale Hospital diabetes 
and audiology clinics.
All patients aged >18 years visiting the diabetes clinic were informed 
about the study, and those who consented to take part completed 
informed consent forms. In addition to their routine comprehensive 
diabetes management, these patients were also directed to the audiology 
clinic, where an appointment for a pure-tone audiometry (PTA) test 
was made. At the audiology assessment, the audiologist presented a 
simple patient symptom questionnaire (tinnitus, vertigo, dizziness 
and HI) before performing PTA. PTA testing was performed by 
trained audiometric technicians using a GSI 67 audiometer (Grason-
Stadler Inc., USA) equipped with TDH-39 supra-aural earphones 
(Telephonics Co., USA) in a dedicated sound-attenuating booth. For 
quality control and quality assurance, the audiometers are calibrated 
annually in accordance with the standards of the American National 
Standards Institute (ISO 389:1991), and biological calibration checks 
were performed daily prior to the first examination. The ambient noise 
level was monitored with a sound-level meter.
Pure-tone air conduction thresholds were measured in dB hearing 
level (dBHL) for both ears at 0.5, 1.0 and 2.0  kHz and averaged for 
each ear. Hearing loss was defined as a pure-tone average of thresholds 
at 0.5, 1.0 and 2.0  kHz of >25 dB in both right and left ears. Like Bener 
et al.,[39] we defined the spectrum of HI in our study as: (i) mild – 
26 - 40 dBHL; (ii) mild to moderate – 41 - 55 dBHL; (iii) moderate to 
severe – 56 - 70 dBHL; (iv) severe – 71 - 90 dBHL; and (v) profound  – 
91 - 120 dBHL.
Optimal glycaemic control was defined as in the SA diabetes 
guidelines as HbA1c ≤7%.[40] HbA1c levels were determined using a 
National Glycohaemoglobin Standardisation Programme-accredited 
turbidimetric inhibition immunoassay for haemolysed whole blood 
on a Siemens Dimension EXL 200 apparatus (Siemens Healthcare 
Diagnostics Inc., Germany).
Height, weight and sitting blood pressure were measured by trained 
nurses. BMI was calculated as kg/m2. GFRs were used to stratify renal 
impairment (Kidney Disease: Improving Global Outcomes (KDIGO) 
2012 chronic kidney disease criteria).[41]
Fundoscopy was performed by the Edendale Hospital 
ophthalmology clinic, and retinopathy was classified as non-
proliferative or proliferative. The diagnosis of peripheral sensory 
neuropathy was made from both a history of paraesthesiae and 
clinical examination.
The Edendale Hospital diabetes data sheet was used for data 
collection. This has been approved by the University of KwaZulu-
Natal Biomedical Research and Ethics Committee (UKZN BREC) 
(ref. no. BCA 194/15). Ethics approval for this study was obtained 
from the UKZN BREC (ref. no. BE 250/19).
Results
Demographics
A total of 296 PLWD were enrolled in the study, with the majority 
(89.2%) having type 2 DM (T2DM) (n=264 v. 32, respectively; 
p<0.001).
Table 1 describes the differences noted when the overall cohort was 
subdivided according to type of DM. Compared with patients with 
type 1 DM (T1DM), those with T2DM were significantly older, had 
had DM for longer and had a higher prevalence of HPT, and T2DM 
was more prevalent in females. HIV infection was significantly more 
common in patients with T1DM. Glycaemic control was suboptimal 
in both types of DM, patients with T1DM having significantly 
poorer control. Over half of the patients with T2DM (51.1%) were 
obese. Patients with T2DM had a substantially higher prevalence 
of diabetes-related complications (non-proliferative retinopathy, 
sensory neuropathy, and renal impairment with GFR <60 mL/
min/1.73 m2) and symptoms of dizziness, vertigo, tinnitus and 
subjective HI than those with T1DM (p<0.001).
A significant proportion of patients in the entire cohort had 
suboptimal glycaemic control (n=233/296; 78.7%). This was 
particularly evident in female patients with T2DM (p<0.001). 
Patients with comorbidities in the form of HPT, obesity and HIV 
infection and those on antiretroviral therapy (ART) had significantly 
poorer glycaemic control than those without comorbidities (p<0.05). 
Diabetes-related complications in the form of sensory neuropathy, 
non-proliferative and proliferative retinopathy, and renal impairment 
were more common in patients with HbA1c >7% (p<0.05). Reported 
symptoms of vertigo and tinnitus were more prevalent in patients with 
poor glycaemic control (p<0.001). Confirmed HI was considerably 
more common in patients with HbA1c >7% (p<0.001), especially 
in the mild to moderate and moderate to severe categories. Bilateral 
ear involvement was more common in patients with suboptimal 
glycaemic control (p<0.001). A significant number of patients aged 
>50 years, with a BMI >25 and with suboptimal lipid control had 
relatively poor glycaemic control (p<0.001).
Analysis of patients with HI
A total of 154 PLWD (52.0%) had confirmed HI, with 201 individual 
ears being identified as affected.
The categories of HI found (in descending order of frequency) 
were mild to moderate, mild, moderate to severe, severe and 
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Table 1. Subdivision of patient population according to type of DM (N=296)
Type 1 DM (N=32; 10.8%) Type 2 DM (N=264; 89.2%) p-value
Age (years), median (IQR) 29.5 (22.5 - 34) 59 (61 - 67) <0.001
Gender, n (%)
Male 13 (40.6) 54 (20.5) <0.001
Female 19 (59.4) 210 (79.5) <0.001
Duration of DM (years), median (IQR) 6.5 (3 - 12) 9 (4 - 17) 0.049
Patients with HPT, n (%) 10 (31.3) 243 (92.1) <0.001
HIV-infected patients, n (%) 9 (28.1) 36 (13.6) <0.001
Patients on ART, n (%) 8 (25.0) 30 (11.4) <0.001
Test results, median (IQR)
HbA1c (%) 10.6 (8.96 - 11.35) 9.2 (7.4 - 10.9) 0.02
TC (mmol/L) 4.3 (3.5 - 5.5) 4.4 (3.6 - 5.1) 0.668
Triglycerides (mmol/L) 0.98 (0.83 - 1.61) 1.48 (1.03 - 1.46) 0.006
HDL-C (mmol/L) 1.19 (1.04 - 1.75) 1.22 (1.03 - 1.46) 0.375
LDL-C (mmol/L) 2.68 (1.85 - 3.79) 2.3 (1.69 - 3.06) 0.147
CD4 count (cells/µL) 559 (491 - 913) 600 (409.25 - 954.5) 0.745
Creatinine (mmol/L) 62 (55.25 - 75.24) 83 (66 - 119) <0.001
BMI (kg/m2) 26 (22.75 - 30.25) 32 (28 - 38) <0.001
Urinary PCR 0.01 (0.01 - 0.123) 0.03 (0.018 - 0.123) 0.475
Diabetes-related complications, n (%)
Non-proliferative retinopathy 3 (9.4) 25 (9.5) <0.001
Proliferative retinopathy 0 8 (3.0) -
Sensory neuropathy 9 (28.1) 127 (48.1) <0.001
Antidiabetic therapy, n (%)
Metformin only 0 17 (6.4) -
Insulin only 27 (84.4) 134 (50.8) <0.001
OADs plus insulin 5 (15.6) 111 (42.0) <0.001
Patient characteristics, n (%)
Age (years)
≤50 31 (96.9) 59 (22.4) 0.003
>50 1 (3.1) 205 (77.7) <0.001
Duration of DM (years)
≤10 23 (71.9) 138 (52.3) <0.001
>10 9 (28.1) 111 (42.1) <0.001
BMI* (kg/m2)
≤25 13 (40.6) 39 (14.8) <0.001
>25 16 (5) 201 (76.1) <0.001
HbA1c (%)
≤7 2 (6.3) 49 (18.6) <0.001
>7 30 (93.8) 203 (76.9) <0.001
TC* (mmol/L) 
≤4 12 (37.5) 95 (36.0) <0.001
>4 19 (59.4) 153 (58.0) <0.001
Triglyceride* (mmol/L) 
≤1.7 24 (75.0) 149 (56.4) <0.001
>1.7 7 (21.9) 94 (35.6) <0.001
HDL-C* (mmol/L) 
≤1.2 14 (43.8) 96 (36.4) <0.001
>1.2 13 (40.6) 109 (41.3) <0.001
LDL-C* (mmol/L) 
≤1.8 4 (12.5) 54 (20.5) <0.001
>1.8 20 (62.5) 105 (39.8) <0.001
Creatinine* (mmol/L)
≤104 29 (90.6) 169 (64.0) <0.001
>104 2 (6.3) 79 (29.9) <0.001
Continued ...
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profound (33.8% v. 25.9% v. 23.9% v. 11.4% v. 5.0%, respectively). 
Aproximately half (n=76/154; 49.4%) of PLWD with HI had bilateral 
ear involvement across all categories of HI (p<0.001). Patients with 
T2DM had a significantly higher prevalence of HI (both unilateral 
and bilateral; p<0.001) in all HI categories.
Table 2 demonstrates that the cohort of patients with confirmed 
HI were significantly older than those without HI, had had DM for 
longer, had a higher prevalence of concomitant HPT and sensory 
neuropathy, higher creatinine levels and lower GFRs, mostly had 
T2DM, and had a higher prevalence of dizziness and self-reported 
hearing loss.
The majority of PLWD aged >60 years had HI (n=82 v. 26; p<0.001). 
In the HI cohort, bilateral ear involvement was significantly more 
common than unilateral disease (p<0.001). No significant difference 
(p<0.05) was noted with regard to the side of ear involvement.
Table 3 shows that the prevalences of HPT and sensory neuropathy 
were significantly higher in the severe and profound HI categories. 
The majority of patients with HI were aged >40 years (93.7%), with 
53.1% of these patients being >60 years old. The mild to moderate 
HI category was more common in patients aged 41 - 60 years, 
usually with a duration of DM ≤10 years, while mild to moderate 
and moderate to severe categories were most common in patients 
aged >60 years. A significant proportion of patients across all HI 
categories had a BMI >25 (p<0.05). TC was significantly elevated in 
patients in the mild and moderate to severe categories, while LDL-C 
was elevated in the mild HI category (p<0.05). Glycaemic control was 
suboptimal across all HI categories (p=0.011). Approximately half of 
the patients with confirmed HI had subjective symptoms of dizziness, 
tinnitus and hearing loss, and just over a quarter reported vertigo.
Subdivision of patient cohort based on HIV status
Approximately half of PLWD with HIV infection had evidence of HI 
(n=22/45; 48.9%). Table 4 shows that mild and severe categories of HI 
were significantly more common in HIV-infected PLWD compared 
with their HIV-uninfected counterparts. These PLWD and HIV with 
HI were significantly younger (p<0.001) and had higher TC levels 
(p=0.044) compared with PLWD without HIV infection.
Symptoms of HI
Vertigo and tinnitus occurred more frequently in patients aged 41 - 60 
years, while tinnitus and subjective hearing loss were more common 
in those aged >60 years. Table 5 shows that PLWD with suboptimal 
glycaemic control, those with a BMI >25 and female patients with 
T2DM had a significantly higher prevalence of all four symptoms.
The majority of patients with HI had HPT as a comorbidity, 
while over half of the patients with HI who reported any of the four 
symptoms also had elevated TC and/or LDL-C levels.
Mild to moderate HI was mostly associated with symptoms of 
vertigo (p=0.019) and subjective hearing loss (p=0.035). Moderate 
to severe HI was associated with dizziness (p=0.024), vertigo 
(p=0.036) and subjective hearing loss (p<0.001), while both severe 
and profound HI were significantly related to subjective hearing 
loss (p=0.007 and p=0.018, respectively). No significant association 
was noted between the mild category and any of the four symptoms, 
which shows that this stage of HI is easy to miss without proper 
audiological screening.
All four symptoms were significantly associated with female gender. 
Dizziness, tinnitus and subjective hearing loss were associated with 
T2DM (p<0.05), while subjective hearing loss was strongly associated 
with HPT (p=0.004), a lower GFR (p=0.004), sensory neuropathy 
(p=0.001) and total HI (p<0.001) (Table 5).
In univariate analysis, the unadjusted odds ratio revealed that HI 
was significantly associated with T2DM, HPT, sensory neuropathy, 
duration of DM ≤10 years, age >50 years, a lower GFR and elevated 
creatinine levels. No significant relationship was found between HIV 
status, ART use, weight and HI. A significant association was found 
between symptoms (dizziness, vertigo, subjective hearing loss) and 
objective HI (Table 6).
After adjusting for age and gender, age >50 years and lower HDL-C 
were significantly associated with HI. Patients with HPT and elevated 
LDL-C were at 4.22 and 3.81 times greater risk of developing HI, 
respectively, while patients who had poorer HbA1c, non-proliferative 
retinopathy and sensory neuropathy were at 2.03 v. 1.35 v. 1.3 times 
greater risk of developing HI (Table 7).
Discussion
DM is a multisystem disease that is capable of inflicting damage to the 
auditory nerve through its micro- and macrovascular complications. 
However, there is a dearth of literature from Africa on the association 
between DM and HI and the need for audiological screening in 
routine diabetes care.
The bulk of our patient cohort were female, of older age, had 
comorbidities in the form of T2DM, HPT and obesity, and had 
diabetes-related complications (non-proliferative retinopathy, 
peripheral sensory neuropathy, and renal impairment as determined 
by higher creatinine levels and a lower GFR).
Table 1. (continued) Subdivision of patient population according to type of DM (N=296)
Type 1 DM (N=32; 10.8%) Type 2 DM (N=264; 89.2%) p-value
GFR* (mL/min/1.73 m2)
<60 2 (6.3) 108 (40.9) <0.001
≥60 29 (90.6) 140 (53.0) <0.001
Symptoms reported, n (%)
Dizziness 8 (25.0) 112 (42.4) <0.001
Vertigo 5 (15.6) 59 (22.4) <0.001
Tinnitus 9 (28.1) 119 (45.1) <0.001
Subjective HI 4 (12.5) 118 (44.7) <0.001
Confirmed hearing loss, n (%) 
Right ear 4 (12.5) 131 (49.6) <0.001
Left ear 4 (12.5) 136 (51.5) <0.001
Bilateral involvement 3 (9.4) 73 (27.7) <0.001
DM = diabetes mellitus; IQR = interquartile range; HPT = hypertension; ART = antiretroviral therapy; HbA1c = glycated haemoglobin; TC = total cholesterol;  
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; BMI = body mass index; PCR = protein/creatinine ratio; OADs = oral antidiabetics;  
GFR = glomerular filtration rate; HI = hearing impairment.
*Variables with missing data.
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Table 2. Differences between the cohorts with and without HI (N=296)
No HI (N=142; 48.0%) HI (N=154; 52.0%) p-value
Age (years), median (IQR) 50 (38 - 59) 62.5 (55 - 70) <0.001 
Gender, n (%)
Male 34 (23.9) 33 (21.4) 0.903
Female 108 (76.1) 121 (78.6) 0.390
Male v. female p<0.001 p<0.001
Type of DM, n (%)
T1DM 27 (19.0) 5 (3.2) <0.001
T2DM 115 (81.0) 149 (96.8) <0.001
Duration of DM (years), median (IQR) 7 (3 - 13) 11 (5 - 18) <0.001
Patients with HPT, n (%) 107 (75.4 ) 146 (94.8) 0.014
HIV-infected patients, n (%) 23 (16.2) 22 (14.3) 0.746
Patients on ART, n (%) 17 (12.0) 21 (13.6) 0.516
Test results, median (IQR)
HbA1c (%) 9.8 (7.53 - 11.1) 9.1 (7.5 - 10.95) 0.312
TC (mmol/L) 4.4 (3.5 - 5.2) 4.4 (3.6 - 5.2) 0.637
Triglyceride (mmol/L) 1.41 (0.95 - 1.93) 1.5 (0.1 - 2.36) 0.116
HDL-C (mmol/L) 1.17 (1.01 - 1.52) 1.24 (1.06 - 0.48) 0.499
LDL-C (mmol/L) 2.36 (1.78 - 3.12) 2.39 (1.66 - 3.18) 0.696
CD4 count (cells/µL) 678 (497.75 - 882.5) 511 (405.5 - 944.5) 0.58
Creatinine (mmol/L) 71 (59 - 89.5) 95.5 (68 - 145) <0.001
BMI (kg/m2) 32 (26.5 - 38) 31 (28 - 37) 0.724
Urinary PCR 0.02 (0.01 - 0.1) 0.03 (0.02 - 0.09) 0.236
Diabetes-related complications, n (%)
Non-proliferative retinopathy 11 (7.8) 17 (11.0) 0.257
Proliferative retinopathy 3 (2.1) 5 (3.3) 0.480
Sensory neuropathy 56 (39.4) 80 (52.0) 0.04
Antidiabetic therapy, n (%)
Metformin only 7 (4.9) 10 (6.5) 0.467
Insulin only 70 (49.3) 91 (59.1) 0.098
OADs plus insulin 51 (35.9) 47 (30.5) 0.686
Patient characteristics, n (%)
Age (years)
≤50 73 (51.4) 17 (11.0) <0.001
>50 69 (48.6) 137 (89.0) <0.001
Duration of DM* (years)
≤10 90 (63.4) 71 (46.1) 0.134
>10 45 (31.7) 75 (48.7) 0.006
BMI* (kg/m2)
≤25 27 (19.0) 25 (16.2) 0.782
>25 101 (71.1) 116 (75.3) 0.309
HbA1c* (%)
≤7 25 (17.0) 26 (16.9) 0.889
>7 110 (77.5) 123 (79.9) 0.394
TC* (mmol/L)
≤4 53 (37.3) 54 (35.1) 0.923
>4 79 (55.6) 93 (60.4) 0.286
Triglyceride* (mmol/L)
≤1.7 87 (61.3) 86 (55.8) 0.86
>1.7 42 (29.6) 59 (38.3) 0.091
HDL-C* (mmol/L)
≤1.2 57 (40.1) 53 (34.4) 0.703
>1.2 51 (35.9) 71 (46.1) 0.070
LDL-C* (mmol/L)
≤1.8 28 (19.7) 30 (19.5) 0.793
>1.8 62 (43.7) 63 (40.9) 0.929
Continued ...
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Table 3. HI groups stratified by demographic, clinical and biochemical variables (N=201)
Mild (N=52)
Mild to mod. 
(N=68)




Age (years), median (IQR) 59.5 (54.5 - 67.5) 62.5 (56 - 70.5) 67 (60 - 73) 66.5 (59 - 77) 62.5 (55 - 70) 0.10
Gender, n (%)
Males (N=39) 12 (23.1) 12 (17.7) 7 (14.6) 4 (17.4) 4 (40.0) 0.08
Females (N=162) 40 (76.9) 56 (82.3) 41 (85.4) 19 (82.6) 6 (60.0) <0.001
Type of DM, n (%)
T1DM (N=5) 0 3 (4.4) 2 (4.2) 0 0 0.09
T2DM (N=196) 52 (100) 65 (95.6) 46 (95.8) 23 (100) 10 (100) <0.001
Duration of DM (years), median (IQR) 18 (3 - 18) 12 (6 - 18) 13 (7 - 18) 9 (4.75 - 19) 9 (6 - 13) 0.57
Patients with HPT (N=193), n (%) 50 (96.2) 64 (94.1) 45 (93.8) 23 (100) 10 (100) <0.001
HIV-infected patients (N=29), n (%) 9 (17.3) 10 (14.7) 5 (10.4) 4 (17.4) 1 (10.0) 0.050
Patients on ART (N=27), n (%) 9 (17.3) 10 (14.7) 3 (6.25) 4 (17.4) 1 (10.0) 0.023
Test results, median (IQR)
HbA1c (%) 9.3 (7.35 - 11.6) 9.4 (8.43 - 11.48) 8.7 (7.55 - 9.5) 9.4 (7.4 - 10.9) 7.5 (6.83 - 
9.05)
0.04
TC (mmol/L) 4.4 (3.88 - 4.92) 4.55 (3.6 - 5.4) 4.55 (3.6 - 5.5) 4.35 (3.5 - 5.4) 3.7 (3.38 - 
4.88)
0.79
Triglyceride (mmol/L) 1.33 (0.93 - 2.17) 1.65 (1.17 - 2.52) 1.5 (0.99 - 2.19) 1.49 (1.28 - 
2.86)
1.05 (1.0 - 
2.03)
0.88
LDL-C (mmol/L) 2.41 (1.85 - 3.05) 2.13 (1.66 - 2.99) 2.3 (1.66 - 3.37) 2.11 (1.29 - 
3.33)
2.03 (1.4 - 
2.89)
0.90
HDL-C (mmol/L) 1.23 (1.05 - 1.41) 1.23 (1.05 - 1.52) 1.29 (1.07 - 
1.49)
1.22 (1.11 - 
1.46)
1.11 (0.96 - 
1.13)
0.21
CD4 (cells/µL) 726.5 (413 - 
1 061)
521 (468.02 - 
782.57)
936 (609 - 
1 795.5)
182 (46.25 - 
312.5)
182 (182) 0.04
Creatinine (mmol/L) 78 (67 - 131.63) 91 (68.24 - 133.36) 91 (68.25 - 
133.36)
94.49 (98 - 151) 101.5 (65 - 
144)
0.22
BMI (kg/m2) 30 (26 - 34.49) 32 (28.75 - 38) 30 (28 - 37.15) 30 (27 - 40) 28.5 (28 - 32) 0.48
Urinary PCR 0.04 (0.01 - 0.2) 0.03 (0.01 - 0.17) 0.03 (0.02 - 0.06) 0.02 (0.05 - 0.16) 0.06 (0.05 - 
0.10)
0.50
Diabetes-related complications, n (%)
Non-proliferative retinopathy (N=24) 6 (11.5) 9 (13.2) 7 (14.6) 2 (8.7) 0 0.022
Proliferative retinopathy (N=5) 0 3 (4.4) 0 2 (8.7) 0 0.091
Sensory neuropathy (N=109) 27 (51.9) 37 (54.4) 23 (47.9) 15 (65.2) 7 (70.0) <0.001
Antidiabetic therapy, n
Metformin only 4 6 4 7 0 <0.001
Insulin only 28 41 30 6 6 <0.001
OADs plus insulin 19 19 12 10 4 0.004
Continued ...
Table 2. (continued) Differences between the cohorts with and without HI (N=296)
No HI (N=142; 48.0%) HI (N=154; 52.0%) p-value
GFR* (mL/min/1.73 m2)
<60 28 (19.7) 82 (53.3) <0.001
≥60 105 (73.9) 64 (41.6) 0.002
Creatinine* (mmol/L)
≤104 112 (78.9) 86 (55.8) 0.065
>104 21 (14.8) 60 (39.0) <0.001
Symptoms reported, n (%)
Dizziness 49 (34.5) 71 (46.1) 0.045
Vertigo 25 (17.6) 39 (25.3) 0.08
Tinnitus 55 (38.7) 73 (47.4) 0.112
Subjective HI 36 (25.4) 86 (55.8) <0.001
HI = hearing impairment; IQR = interquartile range; DM = diabetes mellitus; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; HPT = hypertension;  
ART = antiretroviral therapy; HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;  
BMI = body mass index; PCR = protein/creatinine ratio; OADs = oral antidiabetics; GFR = glomerular filtration rate.
*Variables with missing data.
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A significant majority of patients had suboptimal glycaemic control. 
Poor control was associated with comorbidities (HPT, obesity and 
HIV infection) and being on ART. In the cohort of patients with 
suboptimal glycaemic control, there was a significantly higher 
prevalence of diabetes-related complications (sensory neuropathy, 
non-proliferative retinopathy and renal impairment), more reported 
symptoms of HI (dizziness, tinnitus, vertigo and subjective HI), 
confirmed HI, bilateral HI and poorer lipid control. Patients with 
T2DM had a significantly higher prevalence of reported symptoms 
of HI and confirmed audiological evidence of hearing loss (both 
unilateral and bilateral ear involvement).
Our study demonstrated that over half (52.0%) of PLWD had 
evidence of HI on audiological screening. This is comparable to 
what Idugboe et al.[28] and Hlayisi et al.[38] showed in their studies 
conducted in Nigeria and SA, respectively (52.0% v. 71.4% v. 55%, 
respectively). [28,38] HI in our study was significantly more common 
in patients with T2DM, and when present, was usually bilateral. We 
showed that HI was significantly more prevalent in patients who 
were female, older, had HPT, had had DM for a longer time, and had 
evidence of sensory neuropathy.
Although not statistically significant, there was a higher prevalence 
of HI in PLWD and HIV infection than in their HIV-uninfected 
counterparts. This association deserves more attention in future studies 
including a greater number of HIV-infected patients. In our study, 
PLWD with HIV infection and HI were significantly younger and had 
higher TC levels than their counterparts. Abnormal lipid metabolism is 
associated with both HIV infection and/or ART.[42] DM, HIV infection 
and elevated cholesterol are independent risk factors for cardio vascular 
disease.[20,34,42,43] Our findings suggest a role for audiological screening 
as part of the routine assessment in both HIV and DM management. 
Clinicians treating these patients must screen for HI early in the course 
of DM, especially in young HIV-infected PLWD.
The top three HI categories in our study were mild to moderate, 
mild, and moderate to severe, which differed from the results of 
Table 3. (continued) HI groups stratified by demographic, clinical and biochemical variables (N=201)
Mild (N=52)
Mild to mod. 
(N=68)




Patient characteristics, n (%)
Age (years)
≤50 6 (11.5) 7 (10.3) 4 (8.3) 4 (17.4) 1 (10.0) 0.306
>50 46 (88.5) 61 (89.7) 44 (91.7) 19 (82.6) 9 (90.0) <0.001
Duration of DM* (years) 
≤10 27 (54) 29 (46.8) 19 (41.3) 11 (52.4) 5 (55.6) <0.001
>10 23 (46) 33 (53.2) 27 (58.7) 10 (47.6) 4 (44.4) <0.001
BMI*
≤25 9 (18.4) 10 (16.4) 6 (14) 4 (19) 1 (10.0) 0.061
>25 40 (81.6) 51 (83.6) 37 (86) 17 (81) 9 (90.0) <0.001
HbA1c* (%)
≤7 11 (22.4) 6 (9) 8 (16.7) 4 (19) 3 (33.3) 0.169
>7 38 (77.6) 61 (91) 40 (83.3) 17 (81) 6 (66.7) <0.001
TC* (mmol/L) 
≤4 16 (32.7) 21 (31.8) 17 (35.4) 9 (40.9) 5 (55.6) 0.015
>4 33 (67.3) 45 (68.2) 31 (64.6) 13 (59.1) 4 (44.4) <0.001
Triglyceride* (mmol/L) 
≤1.7 30 (61.2) 35 (53) 32 (68.1) 11 (55) 5 (55.6) <0.001
>1.7 19 (38.8) 31 (47) 15 (31.9) 9 (45) 4 (44.4) <0.001
HDL-C* (mmol/L) 
≤1.2 18 (42.9) 22 (43.1) 16 (38.1) 8 (44.4) 7 (87.5) 0.018
>1.2 24 (57.1) 29 (56.9) 26 (61.9) 10 (56.6) 1 (12.5) <0.001
LDL-C* (mmol/L) 
≤1.8 8 (25) 13 (38.2) 12 (36.4) 6 (46.2) 4 (50.0) 0.142
>1.8 24 (75) 21 (61.8) 21 (63.6) 7 (53.8) 4 (50.0) <0.001
GFR* (mL/min/1.73 m2)
<60 22 (46.8) 35 (52.2) 28 (60.9) 15 (68.2) 7 (77.8) <0.001
≥60 25 (53.2) 32 (47.8) 18 (39.1) 7 (31.8) 2 (22.2) <0.001
Creatinine* (mmol/L)
≤104 30 (63.8) 43 (64.2) 27 (60) 12 (54.5) 3 (33.3) <0.001
>104 17 (36.2) 24 (35.8) 18 (40) 10 (45.5) 6 (66.7) 0.010
Symptoms reported, n (%)
Dizziness (N=94; 47.8%) 20 (38.5) 31 (45.6) 27 (56.3) 13 (56.5) 3 (30.0) <0.001
Vertigo (N=55; 27.4%) 11 (21.2) 22 (32.4) 16 (33.3) 5 (21.7) 1 (10.0) <0.001
Tinnitus (N=103; 51.2%) 23 (44.2) 35 (51.5) 26 (54.2) 12 (52.2) 7 (70.0) <0.001
Hearing loss (N=118; 58.7%) 24 (46.2) 36 (52.9) 34 (70.8) 16 (69.6) 8 (80.0) <0.001
HI = hearing impairment; IQR = interquartile range; DM = diabetes mellitus; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; HPT = hypertension;  
ART = antiretroviral therapy; HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;  
BMI = body mass index; PCR = protein/creatinine ratio; OADs = oral antidiabetics; GFR = glomerular filtration rate.
*Variables with missing data.
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Table 4. Differences observed between HIV-infected and HIV-uninfected patients with HI (N=154) 
HIV-infected (N=22) HIV-uninfected (N=132) p-value
Total, n (%) 22 (14.3) 132 (85.7) <0.001
Age (years), median (IQR) 52.5 (46 - 57) 65 (57 - 71) <0.001
Duration of DM (years), median (IQR) 8 (4.25 - 13.25) 11 (5 - 19) 0.078
Test results, median (IQR)
HbA1c (%) 9.6 (7.7 - 12.1) 9.1 (7.5 - 10.88) 0.304
TC (mmol/L) 4.75 (4.4 - 5.6) 4.3 (3.6 - 5.13) 0.044
Triglyceride (mmol/L) 1.51 (1.1 - 2.2) 1.48 (0.9 - 2.3) 0.647
HDL-C (mmol/L) 1.32 (1.16 - 1.58) 1.22 (1.05 - 1.47) 0.157
LDL-C (mmol/L) 2.67 (1.95 - 3.4) 2.39 (1.63 - 3.11) 0.506
Urinary PCR 0.08 (0.03 - 0.23) 0.03 (0.02 - 0.06) 0.284
Creatinine (mmol/L) 99 (67.24 - 140.14) 95 (65.75 - 146.23) 0.874
BMI (kg/m2) 29 (25 - 32) 31.5 (28 - 38) 0.082
Categories of HI, n (%)
Mild 9 (20.5) 43 (16.3) <0.001
Mild to moderate 10 (22.7) 58 (22) 0.002
Moderate to severe 5 (11.4) 43 (16.3) <0.001
Severe 4 (9.1) 19 (7.2) 0.002
Profound 1 (2.3) 9 (3.4) 0.011
HI = hearing impairment; IQR = interquartile range; DM = diabetes mellitus; HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol;  
LDL-C = low-density lipoprotein cholesterol; PCR = protein/creatinine ratio; BMI = body mass index.
Table 5. Analysis of reported symptoms of HI
Dizziness (N=120) Vertigo (N=64) Tinnitus (N=128) Hearing loss (N=122) p-value
Age (years), median (IQR) 58 (50.5 - 65) 56 (47 - 61.5) 58 (50.5 - 66) 60.5 (53 - 68) 0.03
Duration of DM (years), median (IQR) 9 (4 - 15.75) 8 (5 - 17) 10.5 (5.5 - 17) 9 (5 - 17) 0.734
Gender, n (%)
Female 105 (87.5) 56 (87.5) 109 (85.2) 105 (86.1) <0.001
Male 15 (12.5) 8 (12.5) 19 (14.8) 17 (13.9) 0.198
Type of DM, n (%)
T1DM 8 (6.7) 5 (7.8) 9 (7.0) 4 (3.3) 0.455
T2DM 112 (93.3) 59 (92.2) 119 (93.0) 118 (96.7) <0.001
Patients with HPT, n (%) 105 (87.5) 53 (82.8) 112 (87.5) 113 (92.6) <0.001
HIV-infected patients, n (%) 19 (15.8) 10 (15.6) 22 (17.2) 19 (15.6) 0.201
Patients on ART, n (%) 13 (10.8) 8 (12.5) 19 (14.8) 16 (13.1) 0.194
Test results, median (IQR)
HbA1c (%) 9.7 (7.58 - 11.1) 10.5 (8.4 - 11.3) 9.3 (7.6 - 11.1) 9.2 (7.2 - 10.8) 0.487
TC (mmol/L) 4.5 (3.7 - 5.4) 4.5 (3.6 - 5.2) 4.4 (3.5 - 5.1) 4.6 (3.6 - 5.3) 0.773
Triglyceride (mmol/L) 1.58 (1.05 - 2.51) 1.45 (0.97 - 2.18) 1.39 (0.99 - 2.23) 1.59 (1.07 - 2.29) 0.294
HDL-C (mmol/L) 1.22 (1.03 - 1.5) 1.32 (1.11 - 1.54) 1.16 (1.01 - 1.44) 1.22 (1.07 - 1.46) 0.173
LDL-C (mmol/L) 2.39 (1.73 - 3.15) 2.4 (1.74 - 3.14) 2.21 (1.7 - 2.99) 2.3 (1.66 - 3.01) 0.838
CD4 (cells/µL) 559.11 (450.31 - 
860.45)
518 (476.67 - 
736.63)
519.5 (405.31 - 
820.29)
618 (397.95 -  
1 110.36)
0.617
Creatinine (mmol/L) 83 (67.25 - 118.75) 74 (59.5 - 107.41) 81 (65 - 123) 93 (66 - 129) 0.243
BMI (kg/m2) 32 (28 - 39) 31 (29 - 39) 32 (28 - 38) 31 (28 - 38) 0.707
Urinary PCR 0.03 (0.02 - 0.07) 0.08 (0.04 - 0.22) 0.06 (0.02 - 0.10) 0.03 (0.02 - 0.06) 0.406
Diabetes-related complications, n (%)
Non-proliferative retinopathy 7 (5.8) 8 (12.5) 13 (10.2) 12 (9.8) 0.457
Proliferative retinopathy 2 (1.7) 2 (3.1) 5 (3.9) 3 (2.5) 0.572
Sensory neuropathy 66 (55) 35 (54.7) 69 (53.9) 70 (57.4) 0.003
Antidiabetic therapy, n (%)
Metformin alone 9 (7.5) 7 (10.9) 6 (4.7) 6 (4.9) 0.836
Insulin alone 62 (51.7) 32 (50.0) 71 (55.5) 70 (57.4) <0.001
OADs + insulin 43 (35.8) 23 (35.9) 47 (36.7) 41 (33.6) 0.032
Continued ...
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Idugboe’s study, in which mild, moderate and severe were the top HI 
categories. In the HIV-infected cohort, mild and severe HI were the 
most frequent categories encountered. A significant proportion of 
patients across all categories of HI had a BMI >25, highlighting the 
underlying interaction between obesity, DM and HI.
Approximately half of the PLWD with confirmed HI reported 
symptoms of dizziness, tinnitus and subjective hearing loss, while a 
quarter of these patients had vertigo. Significant associations were 
noted between dizziness, tinnitus and subjective hearing loss and 
audiological evidence of HI. These associations are important, as they 
highlight the need for thorough history-taking from PLWD during 
routine clinic visits. Early detection of HI can facilitate appropriate 
audiology referrals together with enhanced lifestyle and therapeutic 
interventions. No significant association was noted between the mild 
category and any of the four symptoms. Mild HI is therefore easy to 
miss, which strengthens the case for annual audiological assessments 
in PLWD.
We showed that HI was significantly associated with T2DM, HPT, 
sensory neuropathy, age >50 years, a lower GFR and high creatinine 
levels. A significant proportion of these patients with HI had had DM 
Table 5. (continued) Analysis of reported symptoms of HI
Dizziness (N=120) Vertigo (N=64) Tinnitus (N=128) Hearing loss (N=122) p-value
Patient characteristics, n (%)
Age (years)
≤50 30 (25) 23 (35.9) 32 (25.0) 23 (18.9) 0.485
>50 90 (75) 41 (64.1) 96 (75.0) 99 (81.2) <0.001
Duration of DM (years)
≤10 63 (54.8) 36 (56.3) 60 (46.9) 60 (49.2) 0.033
>10 52 (45.2) 22 (34.4) 60 (46.9) 54 (44.3) <0.001
BMI* (kg/m2)
≤25 18 (16.8) 8 (12.5) 16 (12.5) 15 (12.3) 0.263
>25 89 (83.2) 45 (70.3) 104 (81.3) 96 (78.7) <0.001
HbA1c* (%)
≤7 22 (18.8) 7 (10.9) 21 (16.4) 23 (18.9) 0.025
>7 95 (81.2) 53 (82.8) 101 (78.9) 94 (77.1) <0.001
TC* (mmol/L)
≤4 36 (31.6) 22 (34.4) 46 (35.9) 38 (31.2) 0.038
>4 78 (68.4) 37 (57.8) 76 (57.8) 72 (59.0) <0.001
Triglyceride* (mmol/L)
≤1.7 67 (59.3) 39 (60.9) 76 (59.4) 62 (50.8) 0.007
>1.7 46 (40.7) 20 (31.3) 45 (35.2) 46 (35.7) 0.006
HDL-C* (mmol/L)
≤1.2 46 (49.5) 16 (25.0) 59 (46.1) 42 (34.4) <0.001
>1.2 47 (50.5) 33 (51.6) 50 (39.1) 53 (43.4) 0.162
LDL-C* (mmol/L)
≤1.8 25 (34.2) 11 (17.2) 31 (24.2) 27 (22.1) 0.021
>1.8 48 (65.8) 29 (45.3) 58 (45.3) 45 (36.9) 0.022 
GFR* (mL/min/1.73 m2)
<60 52 (45.2) 23 (35.9) 49 (38.3) 60 (49.2) <0.001
≥60 63 (54.8) 37 (57.8) 69 (53.9) 54 (44.3) 0.015
Creatinine* (mmol/L)
≤104 77 (67) 45 (70.3) 81 (63.3) 74 (60.7) 0.009
>104 38 (33) 15 (23.4) 37 (28.9) 40 (32.8) 0.005
Patients reporting symptoms of, n (%)
Dizziness 120 (100) 40 (62.2) 69 (53.9) 65 (53.3) <0.001
Vertigo 40 (25) 64 (100) 35 (27.3) 31 (25.4) 0.001
Tinnitus 69 (57.5) 35 (54.7) 128 (100) 75 (61.5) <0.001
Hearing loss 65 (54.2) 31 (48.4) 75 (58.6) 122 (100) <0.001
Ear involvement, n (%)
Right 64 (53.3) 36 (56.3) 64 (50.0) 76 (62.3) 0.002
Left 67 (55.8) 39 (60.9) 67 (52.3) 80 (65.6) 0.003
Unilateral 11 (9.2) 3 (4.7) 15 (11.7) 16 (13.1) 0.025
Bilateral 60 (50.0) 36 (56.3) 58 (45.3) 70 (57.4) 0.012
HI = hearing impairment; IQR = interquartile range; DM = diabetes mellitus; T1DM = type 1 DM; T2DM = type 2 DM; HPT = hypertension; ART = antiretroviral therapy;  
HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; BMI = body mass index;  
PCR = protein/creatinine ratio; OADs = oral antidiabetics; GFR = glomerular filtration rate.
*Variables with missing data.
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Table 6. Univariate analysis
HI, n
Unadjusted OR (95% CI) p-valueYes No
Age (years)
≤50 17 73 8.526 (4.67 - 5.565) <0.001
>50 137 69
Gender
Male 33 34 0.866 (0.502 - 1.494) 0.606
Female 121 108
Duration of DM (years)
≤10 71 90 2.113 (1.303 - 3.425) 0.002
>10 75 45
Type of DM
T1DM 5 27 <0.001
T2DM 149 115 0.036
HPT
Yes 146 107 5.970 (2.662 - 13.386) <0.001
No 8 35
HIV infection
Yes 22 23 0.881
No 132 119 0.412
ART use
Yes 21 17 0.516
No 133 125 0.618
HbA1c (%)
≤7 26 25 1.075 (0.586 - 1.971) 0.815
>7 123 110
TC (mmol/L)  
>4 54 53 1.155 (0.713 - 1.873) 0.558
≤4 93 79
HDL-C (mmol/L)
<1.2 53 57 1.497 (0.891 - 2.516) 0.127
≥1.2 71 51
Triglyceride (mmol/L)
>1.7 86 87 1.421 (0.866 - 2.332) 0.164
≤1.7 59 42
LDL-C (mmol/L)
>1.8 30 28 0.948 (0.509 - 1.768) 0.868
≤1.8 63 62
BMI (kg/m2)
≤25 25 27 1.24 (0.677 - 2.273) 0.486
>25 116 101
Creatinine (mmol/L)
>104 60 21 3.721 (2.102 - 6.585) <0.001
≤104 86 112
GFR (mL/min/1.73 m2)
≥60 64 105 0.208 (0.123 - 0.354) 0.002
<60 82 28
<15 5 1 0.102
15 - 29 20 4 0.001
30 - 44 30 13 0.010
45 - 59 27 10 0.005
Fundoscopy
Non-proliferative 17 11 1.478 (0.667 - 3.274) 0.336
Proliferative 5 3 1.555 (0.365 - 6.628) 0.551
Sensory neuropathy
Yes 80 56 1.66 (1.046 - 2.634) 0.031
No 74 86
Continued ...
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for ≤10 years. This finding illustrates that HI occurs early in the course 
of DM and must be actively sought for by routine history-taking and/
or audiological screening.
Our study, like those of Lerman-Garber et al.[14] and Agrawal et 
al.,[15] showed that PLWD with HI had significantly poorer glycaemic 
control than those without HI, while studies by Idugboe et al.[28] 
and Hlayisi et al.[38] in Africa did not find any association between 
HI and glycaemic control.[28,38] Our finding sends a strong message 
emphasising the need for improved overall diabetes control. Optimal 
glycaemic control remains elusive globally, especially in developing 
countries,[20] highlighting the need for the introduction of routine 
audiological screening of PLWD.
Our results revealed an association between HI and duration of DM, 
increased age and female gender. In contrast, both Idugboe et al.[28] and 
Hlayisi et al.[38] showed in their studies that HI was associated with 
patient age <50 years. Idugboe et al.[28] further showed that there were 
no associations between HI, duration of DM, glycaemic control or 
gender, and Hlayisi et al.[38] found that HI was more prevalent in males 
and positively associated with duration of DM.
Unlike Idugboe et al.,[28] who found that PLWD on oral anti diabetics 
were at increased risk of developing HI, we found that the majority 
of our patients with HI were on insulin therapy.[28] This is similar to 
results reported by Bainbridge et al.[12] and Bamanie and Al-Noury.[26] 
We postulate that patients requiring insulin therapy are those who have 
uncontrolled DM with suboptimal HBA1c and a resultant increased 
prevalence of HI.
Multivariate analysis revealed that HI was significantly associated 
with age >50 years and a lower level of HDL-C, a subtype of cholesterol 
known to have cardioprotective properties.[34,43] Our results and others 
from Suzuki et al.,[35] Bainbridge et al.[12] and Dabrowski et al.[24] have 
shown that the association between HDL-C and HI must be actively 
searched for. Patients with HPT and elevated LDL-C were at 4.22 times 
and 3.81 times increased risk of developing HI, respectively. We also 
found that HI was more likely in patients with poorer HbA1c, non-
proliferative retinopathy and sensory neuropathy.
Study limitations
A limitation of this study is that all the patients included had DM, 
and there was no control group. However, the study was designed to 
detect the prevalence of HI in PLWD. Future studies comparing HI 
between PLWD and those without DM are envisaged.
Conclusions
Our study showed that older patients, females, and those with 
increased LDL-C and TC, lower HDL-C, suboptimal glucose control, 
non-proliferative retinopathy, sensory neuropathy and obesity were 
Table 6. (continued) Univariate analysis
HI, n
Unadjusted OR (95% CI) p-valueYes No
Antidiabetic therapy
Insulin only 91 70 1.486 (0.938 - 2.353) 0.091
OADs only 7 12 0.516 (0.197 - 1.349) 0.177
Metformin only 10 7 1.339 (0.496 - 3.619) 0.565
OADs plus insulin 47 51 0.784 (0.483 - 1.273) 0.325
Patients reporting symptoms of
Dizziness 71 49 0.045
Vertigo 39 25 0.080
Tinnitus 73 55 0.112
Subjective hearing loss 86 36 <0.001
HI = hearing impairment; OR = odds ratio; CI = confidence interval; T1DM = type 1 DM; T2DM = type 2 DM; HPT = hypertension; ART = antiretroviral therapy;  
HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; BMI = body mass index;  
GFR = glomerular filtration rate; OADs = oral antidiabetics.
Table 7. Multivariate analysis
Adjusted OR p-value
TC 0.284 (0.059 - 1.369) 0.115
Triglyceride 2.330 (0.868 - 6.257) 0.093
HDL-C 3.396 (1.282 - 8.996) 0.014
LDL-C 3.811 (0.825 - 17.598) 0.087
HbA1c 2.032 (0.697 - 5.926) 0.194
GFR >60 (mL/min/1.73 m2) 0.49 (0.142 - 1.690) 0.259
BMI >25 kg/m2 0.411 (0.109 - 1.542) 0.187
Creatinine >104 mmol/L 1.064 (0.268 - 4.226) 0.930
Duration of DM 1.092 (0.434 - 2.749) 0.851
Non-proliferative retinopathy 1.354 (0.256 - 7.148) 0.721
Proliferative retinopathy 0.129 (0.003 - 3.03) 0.204
Sensory peripheral neuropathy 1.296 (0.546 - 3.077) 0.557
HPT 4.220 (0.737 - 24.176) 0.106
Age >50 years 6.885 (2.178 - 21.764) 0.001
Gender 0.852 (0.303 - 2.399) 0.762
OR = odds ratio; TC = total cholesterol; HDL-C = high-density lipoprotein; LDL-C = low-density lipoprotein; HbA1c = glycated haemoglobin; GFR = glomerular filtration rate;  
BMI = body mass index; DM = diabetes mellitus; HPT = hypertension.
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at increased risk of HI. HPT as a comorbidity also increased the 
likelihood of PLWD developing HI. Implementing intervention 
strategies targeting the above risk factors in PLWD would include 
improving physical fitness (known to improve weight, blood pressure, 
glycaemic control and HDL-C levels) and optimising blood pressure 
and glycaemic control as set out in diabetes guidelines. These 
strategies need to be emphasised at all levels of diabetes healthcare.
Symptoms of HI were significantly associated with objective 
evidence of HI for all categories except mild. This finding justifies 
their inclusion in a thorough diabetic history. However, HI cannot 
be excluded purely on the basis of history, as we found that the mild 
category had a poor correlation with symptoms. A high level of 
clinical suspicion is therefore warranted, especially in PLWD with 
HPT and suboptimal glycaemic and lipid control, and in those with 
diabetes-related complications.
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